An activating missense mutation in codon 600 of exon 15 (V600E) of the BRAF gene has been identified in various tumor types, and BRAF inhibitors have yielded clinical benefits for patients with BRAF V600E-mutated cancers, especially melanoma and NSCLC [150–152]. The gene discussed is BRAF; the disease is neoplasm.